Summary
Surgery, chemotherapy and radiotherapy are the current modalities of tumor management. However, in systemic disease, predicted patients’ cure can be achieved in but a few tumor diseases. Based on previous basic research we have highlighted that the loss of cell-cell adhesion in association with an increased tumor cell motility is an essential feature of the malignant potential of bladder tumors. Thus, we have attempted therapeutical methods differing from hitherto existing treatments by focusing on a tumor cell function we call cell motility. Characterization of so-called anti-motility drugs was performed biochemically as well analyzed by in vitro by using in established bladder carcinoma cell lines. We evaluated the potential therapeutic benefit in a model of chemically induced bladder carcinoma followed by a phase I/II trial applying antimotility drugs in patients which were chemotherapy-resistant and having metastatic bladder cancer.
Both basic research as well as the results of first translational clinical trials confirmed, that advanced bladder carcinomas can be favorably affected by inhibition of tumor cell motility.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Otto, T., Birchmeier, W., Schmidt, U., Rembrink, K., Schipper, J., Rübben, H., Raz, A. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with carcinoma of the bladder: Cancer Res. 54: 3120, 1994.
Igawa, M. Limitations of M-VAC chemotherapy for the treatment of advanced bladder carcinomas: J. Urol. 144: 662, 1994.
Otto, T. Be, A., Schmidt, U., Raz, A., Rübben, H.: Improved prognosis assessment for patients with bladder cancer, Am. J. Pathol. 150: 911, 1997.
Otto, T., Be, A., Krege, S., Walz, P.H., Rübben, H.: Paclitaxel based second line therapy for patients with advanced chemotherapy -resistant bladder carcinoma (M1) — A clinical phase II study Cancer 80: 465, 1997.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Otto, T., Lümmen, G., Be, A., Rubben, H., Raz, A. (1999). Tumor Cell Motility. In: Baskin, L.S., Hayward, S.W. (eds) Advances in Bladder Research. Advances in Experimental Medicine and Biology, vol 462. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4737-2_36
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4737-2_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7147-2
Online ISBN: 978-1-4615-4737-2
eBook Packages: Springer Book Archive